कंपनी का अवलोकन
Disc Medicine, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery, development, and commercialization of novel therapeutic interventions for patients suffering from serious hematologic diseases within the United States. The company functions within the Healthcare sector, specifically targeting the Biotechnology industry, which implies a focus on high-risk, high-reward research and development phases before potential commercialization. Currently, the enterprise maintains a market capitalization of $2.57B while employing a workforce of 155 individuals. Although the specific annual revenue figure is not disclosed in the available data, the substantial market cap of $2.57B relative to the current revenue status suggests that the market is valuing the company primarily on the potential of its clinical pipeline rather than established commercial sales, indicating a position typical of pre-revenue or early-stage biotechnology firms where asset value is derived from intellectual property and pipeline progress rather than historical earnings.
वित्तीय स्वास्थ्य
The financial statements for the trailing twelve months reveal a net income of $-212,184,000 and an EBITDA of $-234,888,992, while the revenue figure remains unquantified in the provided data. The significant gap between the reported net income and EBITDA, coupled with the absence of revenue data, indicates a cost structure heavily weighted towards research and development expenses and general administrative costs that have not yet been offset by commercial income. The company reported a free cash flow of $-111,715,624, which signifies a substantial cash outflow required to fund ongoing clinical trials and operational expenditures, reflecting limited immediate financial flexibility without external capital injections. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which indicates that the company has not yet achieved commercial profitability or that revenue figures are insufficient to calculate meaningful margins in the current reporting period. On the balance sheet, the company holds $791.15M in cash against total debt of $31.02M, resulting in a debt-to-equity ratio of 4.19, suggesting a capital structure that is currently leveraged due to equity dilution or low share price rather than operational borrowing. Despite the high debt-to-equity ratio, the current ratio stands at 21.94, indicating an exceptionally strong position in short-term liquidity where current assets vastly exceed current liabilities. The return on equity is -35.9% and the return on assets is -22.5%, metrics that reveal management is currently generating negative returns on the capital invested, a common characteristic for clinical-stage companies prior to product approval and sales.
मूल्यांकन आकलन
The valuation metrics show a P/E Ratio (TTM) of N/A and a Forward P/E of -8.95, a discrepancy that implies earnings are currently negative and the forward metric reflects expected future profitability that has not yet been realized. The price-to-book ratio is 3.45, indicating that the market is pricing the company at a significant premium over its tangible book value, reflecting high expectations for the success of its drug candidates. The price-to-sales ratio and EV/EBITDA are both listed as N/A or -7.70 respectively; the negative EV/EBITDA of -7.70 suggests that the enterprise value is high relative to the negative earnings, a standard valuation for pre-revenue biotech firms where the denominator is negative. The stock has traded within a 52-week range between a high of $99.50 and a low of $30.82, with the current price metrics implying a position that requires specific calculation relative to these bounds to determine the exact percentage distance from the yearly extremes. The beta value of 2.54 indicates that the stock price is highly volatile and expected to fluctuate with significantly greater magnitude than the broader market index, reflecting the binary nature of clinical trial outcomes and regulatory approvals inherent to the biotechnology sector.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, precluding any quantitative comparison of earnings expansion relative to revenue expansion at this stage of the company's lifecycle. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings and cash flows are being retained and reinvested directly into research, development, and commercialization efforts rather than distributed to shareholders. This reinvestment strategy is typical for clinical-stage biopharmaceutical companies where capital allocation is focused on advancing assets through clinical trials to achieve regulatory approval. The overall growth and income profile is characterized by a complete absence of current commercial revenue growth and dividend income, relying entirely on future clinical milestones to drive value creation and eventual profitability.